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Abstract
The rise in antimicrobial resistance has become a serious global health problem. Restrictive use of antibiotics seems the only option to
temper this accession since research in new antibiotics has halted. Antimicrobial stewardship programmes rely on quick access to sus-
ceptibility data. This study evaluated the concept of bacterial cell count monitoring as a fast method to determine susceptibility. Escheri-
chia coli, Pseudomonas aeruginosa and Staphylococcus aureus strains were tested for amoxicillin/piperacillin and gentamicin by three
conventional methods (VITEK2, Etest and broth-macrodilution). Bacterial cell count monitoring reliably predicted susceptibility after
90 min for Escherichia coli and after 120 min for Pseudomonas aeruginosa and Staphylococcus aureus without any minor, major or very
major discrepancies. Time-to-result was reduced by 74%, 83% and 76%, respectively. Bacterial cell count monitoring shows great poten-
tial for rapid susceptibility testing.
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Introduction
Antibiotic resistance has become a global threat to human
health [1]. ‘Super-bugs’ like XDR tuberculosis and NDM1
metallo-betalactamases have emerged and spread globally
[2,3]. Infections caused by multidrug resistant microorganims
are often difﬁcult to treat or can not be treated at all with
antibiotics considered safe enough for the patient. In sharp
contrast to the aforementioned, the development of new
antibiotics has ceased, as demonstrated by the approval of
only two new antibacterial agents based on new molecular
entities since 1998 (linezolid in 2000 and daptomycin
in 2003) [4]. In light of these developments it seems clear
that only very stringent use of antibiotics, for instance by
antibiotic stewardship programmes, may delay the rise of
resistance and ascertain time to stimulate research into new
drugs in the years to come. Switching from empirical broad
spectrum antibiotic therapy to targeted therapy as soon as
possible is one of the cornerstones of antibiotic stewardship
but depends on the rapid availability of antimicrobial suscep-
tibility data. Currently, several automated antimicrobial sus-
ceptibility testing methods are available, of which the
VITEK2 (bioMe´rieux, Marcy-l’E´toile, France) (VITEK) and
the Phoenix (BD Biosciences, Frankklin Lakes, NJ, USA)
system provide the most rapid results (mean time-to-result
9 h) [5]. Translated into daily clinical practice, however, it
means that switching from broad spectrum empirical therapy
to small spectrum targeted therapy will only be instituted
the following working day. It is reasonable to assume that an
earlier switch to targeted antibiotic therapy will have a
decreasing effect on the rise of antimicrobial resistance.
More importantly, rapid susceptibility results will shorten the
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use of inappropriate antibiotics, leading to increased patient
survival [6] and decreased costs [7]. In this article we evalu-
ated the concept of bacterial cell count monitoring using
ﬂow cytometry as a tool to determine antimicrobial suscepti-
bility in antibiotic broth-dilution series. In ﬂow cytometry,
microscopic particles are analysed by suspending them in a
stream of ﬂuid on which a single wavelength laser beam is
focussed. Particles passing the laser beam scatter the light,
which is detected by forward and sideward photosensitive
detectors. Furthermore, ﬂuorescence caused by dyes staining
DNA, RNA or speciﬁc proteins can be detected using ﬂuo-
rescence detectors. The pattern of scattered light is predic-
tive for the size and shape of the particle. Combined with
ﬂuorescence data, cells can be differentiated from other par-
ticles and studied for transformations over time. Currently,
several analysers are capable of analysing substantial quanti-
ties of ﬂuid in a very short amount of time. The Sysmex UF-
1000i ﬂow cytometer (UF) we used in our study was
designed to perform a complete urine sediment analysis
(including the presence of red and white blood cells, epithe-
lial cells, bacteria, mucus, crystals and casts) in only 90 s.
Although the principle of ﬂow cytometry has already been
applied to antimicrobial susceptibility testing since 1982 [8],
all papers published so far studied light scattering patterns,
cell-elongation by DNA/RNA content or differences in dead
and viable cells. None of these studies considered the possi-
bility of bacterial cell counting over time to detect an
increase, equilibrium or decrease in the number of particles
(bacteria). This process obviously precedes the development
of turbidity caused by bacterial growth, on which present-
day conventional methods such as the VITEK and Phoenix
systems are based. In this article we demonstrate the proof-
of-principle of cell count monitoring for antimicrobial suscep-
tibility testing, resulting in a signiﬁcant decrease in time-to-
result.
Materials and Methods
Strains were selected to represent bacterial families of
which the members are most frequently isolated in clinical
samples: Escherichia coli (E. coli) representing the Enterobac-
teriaceae, Pseudomonas aeruginosa (P. aeruginosa) representing
the non-fermenting bacteria, and Staphylococcus aureus
(S. aureus) representing the Staphylococci. Amoxicillin (or
piperacillin in the case of P. aeruginosa) and gentamicin were
the chosen antibiotics to be evaluated because they repre-
sent frequently used empirical antibiotics in patients and
have a completely different mode of action (cell-wall pro-
duction interference vs. protein production interference).
From each aforementioned species four strains, derived
from clinical samples and identiﬁed both by VITEK2 (bio-
Me´rieux) and Biﬂex MALDI-TOF mass spectrometer (Bru-
ker Daltonics, Bremen, Germany), were included. Initial
susceptibility testing was performed by VITEK using CLSI
breakpoints. For each species one strain showing a minimal
inhibitory concentration (MIC) for amoxicillin (or piperacil-
lin) close to the susceptible/resistant breakpoint, one strain
showing a MIC above the resistant breakpoint of amoxicillin
(or piperacillin), one strain showing a MIC for gentamicin
close to the susceptible/resistant breakpoint MIC and one
strain showing a MIC above the resistant breakpoint for
gentamicin was selected. Besides the VITEK analysis, suscep-
tibility testing was also performed by E-test (Etest) (bio-
Me´rieux), and by broth-macrodilution (BMD). VITEK and
Etest susceptibility testing was performed according to the
manufacturers’ guidelines, BMD was performed according to
CLSI criteria [9]. CLSI criteria were chosen over EUCAST
criteria because our laboratory was still using CLSI criteria
at the time the study was performed. For each method of
susceptibility testing, time from initial incubation to test
result (time-to-result) was recorded.
Each strain was plated on a blood agar medium and incu-
bated at 35C ambient atmosphere for 18 h. The next day four
colonies were suspended in 6 mL Muller Hinton (MH) broth
and analysed by the Sysmex UF-1000i ﬂow cytometer (UF). If
necessary, colonies were added until the UF showed a bacte-
rial count of at least 10 000 bacteria/lL but <50 000 bacteria/
lL. These bacterial cell counts were chosen deliberately to
ensure the experiment started with a bacterial concentration
between about 50 and 200 bacteria/lL, as explained in the
next section. The 6 mL suspension was diluted ten-fold by
transferring 2222 lL to a ﬂask containing 20 mL of MH broth.
Subsequently, 1111 lL of this dilution was suspended in 11
ﬂasks each containing 30 mL MH broth. Ten of these ﬂasks
contained the desired antibiotic in concentrations of 0.5, 1, 2,
4, 8, 16, 32, 64, 128 and 256 mg/L (after adding the suspen-
sion). The eleventh ﬂask did not contain the antibiotic and
served as a positive control (PC). A twelfth ﬂask, without the
antibiotic or the bacterial suspension, was added to serve as a
negative control (NC). Each of the 12 ﬂasks was divided over
six aliquots, resulting in six (time-) series of 12 aliquots con-
taining a positive control, a negative control and an antibiotic
dilution series. All aforementioned steps were performed after
vortexing thoroughly. One series (t0) was processed immedi-
ately by the UF to acquire a baseline bacterial cell count and to
eliminate series with unacceptable starting distributions
between the 12 aliquots. All other series were placed in an
incubator at 35C ambient atmosphere. Series t60, t90, t120,
t180 and t240 were processed by the UF after 60, 90, 120, 180
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and 240 min of incubation, respectively. Bacterial counts by
the UF were plotted in Excel (Microsoft, Redmond, WA,
USA) bar-graphs. The results were compared with VITEK,
Etest and BMD results. Discrepancies were determined
according to FDA guidelines [10].
Results
Data obtained for E. coli and S. aureus strains exposed to
amoxicillin and P. aeruginosa strains exposed to piperacillin
are shown in Figures 1–3. The ﬁgures for exposure to genta-
micin showed comparable results (data not shown). All three
gold standard methods (VITEK, Etest and BMD) are com-
monly accepted as reliable procedures to determine or pre-
dict susceptibility. In our study, however, they were not
uniformly in agreement with each other (Table 1). Theoreti-
cally, the MIC for a certain antibiotic should be the lowest
antibiotic concentration at which no increase in cell count
could be observed. Because antibiotics do not work instantly
we anticipated that some bacterial growth would occur
before the effect of the antibiotic could be detected. There-
fore, we considered the MH-broth with the lowest antibiotic
concentration showing a cell count reduction of at least 80%
as compared with the positive control after 240 min as the
predicted MIC by ﬂow cytometry. This deﬁnition resulted in
a 100% correct prediction of the MIC for all strains and all
antibiotics according to the reference methods.To investigate
whether susceptibility could be predicted at an earlier time-
point, smaller reductions in cell count (i.e. 20%, 40% or 60%)
were considered after shorter incubation periods. It
appeared that a 100% correct prediction of the MIC could
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FIG. 1. Escherichia coli strains exposed to
amoxicillin. Bacterial cell counts per microlitre
by ﬂow cytometry over time for an amoxicil-
lin-susceptible (a) and resistant (b) strain of
E. coli. MIC, minimal inhibitory concentration;
NC, negative control; PC, positive control;
BMD, broth-macrodilution; Min, minutes of
incubation at 35C ambient atmosphere.
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FIG. 2. Pseudomonas aeruginosa strains
exposed to piperacillin. Bacterial cell counts
per microlitre by ﬂow cytometry over time
for a piperacillin-susceptible (a) and resistant
(b) strain of P. aeruginosa. MIC, minimal inhibi-
tory concentration; NC, negative control; PC,
positive control; BMD, broth-macrodilution;
Min, minutes of incubation at 35C ambient
atmosphere.
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be made for E. coli already after 90 min of incubation if cell
count was reduced by 60% as compared with the positive
control. Also, in the case of S. aureus a 100% correct predic-
tion could be made if cell count stayed 60% behind, albeit
that this required 120 min of incubation. Even for P. aerugin-
osa the MIC could be 100% correctly predicted after
120 min if cell count was reduced by 40%. This lower per-
centage of ‘growth inhibition’ is understandable, as it is in
line with the commonly known slower growth rate of
P. aeruginosa. All MIC data obtained with the aforementioned
cut-off values are shown in Table 1. According to FDA crite-
ria, no minor, major or very major discrepancies were
observed when ﬂow cytometry was compared with each
individual reference standard [10]. It has to be mentioned,
though, that for the amoxicillin-susceptible S. aureus strain
Etest showed an MIC of 0.125 whereas ﬂow cytometry
showed a decrease of >60% at an amoxicillin concentration
of 0.5 mg/L. As we did not use lower amoxicillin concentra-
tions in our study, this MIC found by Etest could not be con-
ﬁrmed by ﬂow cytometry. Comparison of time-to-result data
between the fastest currently accepted method (VITEK) and
bacterial cell count monitoring are shown in Table 2.
Discussion
Our results clearly demonstrate the proof of principle of bac-
terial cell count monitoring for antimicrobial susceptibility
testing. Antibiotic effects on susceptible strains are crystal
clear after 240 min of incubation. This effect is deﬁnitely
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FIG. 3. Staphylococcus aureus strains exposed
to amoxicillin. Bacterial cell counts per micro-
litre by ﬂow cytometry over time for an
amoxicillin-susceptible (a) and resistant (b)
strain of S. aureus. MIC, minimal inhibitory
concentration; NC, negative control; PC, posi-
tive control; BMD, broth-macrodilution; Min,
minutes of incubation at 35C ambient atmo-
sphere; na, not available.
TABLE 1. Comparison of MICs
found by different methods
Strain
Figure
no.
Antibiotic
tested
VITEK
MIC
Etest
MIC
BMD
MIC
Flow
cytometry
MIC
E. colia 1a Amoxicillin 8 4 8 4
E. colia 1b Amoxicillin ‡32 ‡256 >256 >256
E. colia na Gentamicin £1 0.5 £0.5 1
E. colia na Gentamicin ‡16 32 128 64
P. aeruginosab 2a Piperacillin 8 8 16 16
P. aeruginosab 2b Piperacillin ‡128 ‡256 >256 >256
P. aeruginosab na Gentamicin £1 1.5 2 1
P. aeruginosab na Gentamicin ‡16 ‡256 >256 >256
S. aureusc 3a Amoxicillin na 0.125 £0.5 £0.5
S. aureusc 3b Amoxicillin na 1.5 2 1
S. aureusc na Gentamicin £0.5 0.5 £0.5 £0.5
S. aureusc na Gentamicin ‡16 128 128 128
aLowest antibiotic concentration showing 60% reduction in cell count as compared with the positive control after
90 min of incubation.
bLowest antibiotic concentration showing 40% reduction in cell count as compared with the positive control after
120 min of incubation.
cLowest antibiotic concentration showing 60% reduction in cell count as compared with the positive control after
120 min of incubation.
na, not available; BMD, broth-macrodilution.
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absent in the case of a resistant strain. Compared with the
mean time-to-result of 9 h by currently accepted methods [5],
cell count monitoring using the UF reduced the time-to-result
by 55%. Surprisingly, analysis of the results showed that an
effect of antibiotics on the increase of bacterial cell count
could already be presumed after 60 min of incubation. Reduc-
tion in cell count proved to be capable of a 100% reliable fore-
cast upon the actual MIC and was able to reduce the time-to-
result to 90 min (in the case of E. coli) or 120 min (in the case
of S. aureus and P. aeruginosa). These time-to-results will
reduce the currently accepted standard by at least 74–86%.
Although this tremendous reduction in time-to-result is appre-
ciable the real advantage will be that the chance of prescribing
appropriate targeted antibiotic therapy 1 day earlier increases
signiﬁcantly. This will not only reduce mortality [6] and costs
[7], but may also decelerate the rise of resistance. The study
we performed is not the ﬁrst using ﬂow cytometry to deter-
mine antimicrobial susceptibility. Nearly 40 papers have been
published on this topic since the ﬁrst publication in 1982 by
Steen et al. [8]. During the 1990s ﬂow cytometry was less
developed than nowadays and comprised time consuming pro-
cedures using inefﬁcient dyes on expensive analysers. Investi-
gators studied the ratio of viable/dead cells, cell-elongation,
ﬂuorescence intensity, DNA/RNA content and cell morphol-
ogy when selected bacteria were exposed to antibiotics. Like
our study, most of these studies were able to demonstrate
antibiotic effects on bacterial cells already within 1–2 h after
exposure to antibiotics [11]. However, the procedures used
were too impractical to be accepted in daily clinical practice.
As a result, from 2000 on the interest in ﬂow cytometry for
this purpose waned, according to the number of publications
in the international literature. None of these studies con-
cluded that a change in bacterial cell count over time could be
used as a more easy to perform and reliable predictor of anti-
microbial susceptibility. In 1996 Walberg et al. [12] published a
study including a graph (graph 4) showing that the broth con-
taining an E. coli strain increased rapidly in bacterial count over
time when the strain was incubated without ampicillin or with
a sub-MIC concentration of ampicillin. When the same strain
was incubated with antibiotic concentrations above the MIC
no increase in bacterial count was observed at all. This differ-
ence was already visible after 40 min and became increasingly
visible until the end of the experiment at 100 min. Although
this remarkable ﬁnding was discussed in the results section,
the authors did not mention it in the discussion section. Mason
et al. [13] also reported an increase of bacterial cell count for
the control and sub-MIC antibiotic concentration broths,
whereas above-MIC concentrations cell counts remained sta-
ble. This effect, which was present at least after 60 min, was
not clearly visible in their graph using a log particle counts/mL
scale. Again, these authors did not refer to this ﬁnding in their
discussion section. Nevertheless, these papers support our
idea that bacterial cell count monitoring can be used as a very
fast procedure to reliably predict antimicrobial susceptibility.
The application of cell count monitoring may even go further
as Cohen et al. [14] showed in 1989 that ﬂow cytometry could
reliably predict the presence of antimicrobial susceptibility for
amikacin directly in clinical samples containing polyﬂora. They
showed that amikacin susceptibility was reliably detected
within 1 h in 92% of 13 clinical samples. All the aforemen-
tioned studies used protocols hampered by laborious proce-
dures, suboptimal dyes and high costs. For this reason, more
straightforward and easier to automate turbidity and colori-
metric measuring techniques, used for instance in VITEK,
gained the upper hand and became the standard procedure in
daily laboratory practice. Nowadays, molecular-based detec-
TABLE 2. Comparison of time-to-result between VITEK and bacterial cell count monitoring using the optimal cut-off: for
E. coli and S. aureus, lowest antibiotic concentration showing 60% reduction in cell count as compared with the positive con-
trol; cut-off for P. aeruginosa, lowest antibiotic concentration showing 40% reduction in cell count as compared with the posi-
tive control
Strain
Figure
no.
Antibiotic
tested (S/R)
VITEK
(h:min)
Cell count
monitoring
(h:min)
Reduction
in time-to-
result (%)
E. coli 1a Amoxicillin (S) 7:50 1:30 )80
E. coli 1b Amoxicillin (R) 5:50 1:30 )74
E. coli na Gentamicin (S) 9:50 1:30 )85
E. coli na Gentamicin (R) 6:00 1:30 )75
P. aeruginosa 2a Piperacillin (S) 13:50 2:00 )86
P. aeruginosa 2b Piperacillin (R) 13:25 2:00 )85
P. aeruginosa na Gentamicin (S) 12:00 2:00 )83
P. aeruginosa na Gentamicin (R) 12:00 2:00 )83
S. aureus 3a Amoxicillin (S) na 2:00 na
S. aureus 3b Amoxicillin (R) na 2:00 na
S. aureus na Gentamicin (S) 8:25 2:00 )76
S. aureus na Gentamicin (R) 8:25 2:00 )76
na, antibiotic not avaliable on VITEK2 card; S, susceptible according to CLSI criteria; R, resistant according to CLSI criteria.
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tion of resistance genes or gene-complexes is becoming more
and more popular, supposedly obviating the need for
phenotypic susceptibility testing. These techniques are as yet
time consuming and costly. Moreover, they need specialized
technicians and equipment. The most important drawback,
however, is the inability to detect new and unknown resistance
mechanisms. Thus, molecular techniques may reliably demon-
strate resistance, but cannot reliably predict susceptibility. In
clinical practice, however, the latter is eventually decisive for
the most appropriate antibiotic to be prescribed. In our opin-
ion, phenotypic testing will therefore maintain its important
role in antimicrobial susceptibility testing in the future. During
the past decennia, ﬂow cytometry techniques have improved
considerably. The ﬂow cytometer we used is designed to do a
complete urine sediment analysis in relatively ‘contaminated’
solutions harbouring multiple kinds of bacteria, cells and debris
instead of a bacterial count analysis in an otherwise clean ﬂuid.
Clearly, this analyser is over equipped and not speciﬁcally
designed for our goal. Also, the exact polymethine ﬂuorescent
dye used for staining nucleic acids and proteins is patented and
thus not known to us. We believe there is room for improve-
ment, enabling even shorter time-to-results, when a less com-
plicated and tailor-made ﬂow cytometer is used. Besides ﬂow
cytometry, other techniques such as electrical micro-imped-
ance spectroscopy [15] are being developed, which might even
be better, quicker and cheaper to answer our central question:
increase or not in bacterial cell count.
In conclusion, our study showed that the principle of bacte-
rial cell count monitoring can reliably predict antimicrobial sus-
ceptibility in 90–120 min, decreasing the currently accepted
time-to-result by 74–86% for E. coli, S. aureus and P. aeruginosa
strains. This reduction of time could have a signiﬁcant impact
on mortality, costs and the rise of microbial resistance.
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